Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07693452 · ClinicalTrials.gov registry record · Phase 2
Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms
A Phase 2 study, sponsored by University of California, Irvine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT07693452 is a Phase 2 study that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 15 participants.
The verdict
NCT07693452, a Phase 2 study, is actively recruiting participants, sponsored by University of California, Irvine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritoneal (PMP) secondary to appendiceal mucinous neoplasms (AMNs).
Interventions
- DRUG Metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-06-18 |
| Est. Completion | 2029-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07693452
The ClinicalTrials.gov registry entry for NCT07693452 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Metformin is the first listed.
NCT07693452 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07693452 about?
NCT07693452 is a clinical study titled "Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms". This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritoneal (PMP) secondary to appendiceal mucinous neoplasms (AMNs).
What is the current status of trial NCT07693452?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2026-06-18. Estimated completion is 2029-07.
What interventions are being tested in trial NCT07693452?
The interventions under investigation include: Metformin (DRUG).
Who is sponsoring clinical trial NCT07693452?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.